Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2

Thomas H. Scheuermann, Daniel Stroud, Christopher E. Sleet, Liela Bayeh, Cameron Shokri, Hanzhi Wang, Charles G. Caldwell, Jamie Longgood, John B. MacMillan, Richard K. Bruick, Kevin H. Gardner, Uttam K. Tambar

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Hypoxia inducible factor (HIF) transcription factors reside at the center of signaling pathways used by mammalian cells to sense and respond to low oxygen levels. While essential to maintain oxygen homeostasis, misregulation of HIF protein activity correlates with tumor development and metastasis. To provide artificial routes to target misregulated HIF activity, we identified small molecule antagonists of the HIF-2 transcription factor that bind an internal cavity within the C-terminal PAS domain of the HIF-2α subunit. Here we describe a new class of chiral small molecule ligands that provide the highest affinity binding, the most effective, isoform-selective inhibition of HIF-2 in cells, and trigger the largest protein conformation changes reported to date. The current results further illuminate the molecular mechanism of HIF-2 antagonism and suggest additional routes to develop higher affinity and potency HIF-2 antagonists.

Original languageEnglish (US)
Pages (from-to)5930-5941
Number of pages12
JournalJournal of Medicinal Chemistry
Volume58
Issue number15
DOIs
StatePublished - Jul 30 2015

Fingerprint

Protein Isoforms
Transcription Factors
Oxygen
Protein Conformation
Homeostasis
endothelial PAS domain-containing protein 1
Neoplasm Metastasis
Ligands
Hypoxia
Neoplasms
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2. / Scheuermann, Thomas H.; Stroud, Daniel; Sleet, Christopher E.; Bayeh, Liela; Shokri, Cameron; Wang, Hanzhi; Caldwell, Charles G.; Longgood, Jamie; MacMillan, John B.; Bruick, Richard K.; Gardner, Kevin H.; Tambar, Uttam K.

In: Journal of Medicinal Chemistry, Vol. 58, No. 15, 30.07.2015, p. 5930-5941.

Research output: Contribution to journalArticle

Scheuermann, TH, Stroud, D, Sleet, CE, Bayeh, L, Shokri, C, Wang, H, Caldwell, CG, Longgood, J, MacMillan, JB, Bruick, RK, Gardner, KH & Tambar, UK 2015, 'Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2', Journal of Medicinal Chemistry, vol. 58, no. 15, pp. 5930-5941. https://doi.org/10.1021/acs.jmedchem.5b00529
Scheuermann TH, Stroud D, Sleet CE, Bayeh L, Shokri C, Wang H et al. Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2. Journal of Medicinal Chemistry. 2015 Jul 30;58(15):5930-5941. https://doi.org/10.1021/acs.jmedchem.5b00529
Scheuermann, Thomas H. ; Stroud, Daniel ; Sleet, Christopher E. ; Bayeh, Liela ; Shokri, Cameron ; Wang, Hanzhi ; Caldwell, Charles G. ; Longgood, Jamie ; MacMillan, John B. ; Bruick, Richard K. ; Gardner, Kevin H. ; Tambar, Uttam K. / Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2. In: Journal of Medicinal Chemistry. 2015 ; Vol. 58, No. 15. pp. 5930-5941.
@article{bbfa008d186146d39ac4aeace80a8d04,
title = "Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2",
abstract = "Hypoxia inducible factor (HIF) transcription factors reside at the center of signaling pathways used by mammalian cells to sense and respond to low oxygen levels. While essential to maintain oxygen homeostasis, misregulation of HIF protein activity correlates with tumor development and metastasis. To provide artificial routes to target misregulated HIF activity, we identified small molecule antagonists of the HIF-2 transcription factor that bind an internal cavity within the C-terminal PAS domain of the HIF-2α subunit. Here we describe a new class of chiral small molecule ligands that provide the highest affinity binding, the most effective, isoform-selective inhibition of HIF-2 in cells, and trigger the largest protein conformation changes reported to date. The current results further illuminate the molecular mechanism of HIF-2 antagonism and suggest additional routes to develop higher affinity and potency HIF-2 antagonists.",
author = "Scheuermann, {Thomas H.} and Daniel Stroud and Sleet, {Christopher E.} and Liela Bayeh and Cameron Shokri and Hanzhi Wang and Caldwell, {Charles G.} and Jamie Longgood and MacMillan, {John B.} and Bruick, {Richard K.} and Gardner, {Kevin H.} and Tambar, {Uttam K.}",
year = "2015",
month = "7",
day = "30",
doi = "10.1021/acs.jmedchem.5b00529",
language = "English (US)",
volume = "58",
pages = "5930--5941",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "15",

}

TY - JOUR

T1 - Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2

AU - Scheuermann, Thomas H.

AU - Stroud, Daniel

AU - Sleet, Christopher E.

AU - Bayeh, Liela

AU - Shokri, Cameron

AU - Wang, Hanzhi

AU - Caldwell, Charles G.

AU - Longgood, Jamie

AU - MacMillan, John B.

AU - Bruick, Richard K.

AU - Gardner, Kevin H.

AU - Tambar, Uttam K.

PY - 2015/7/30

Y1 - 2015/7/30

N2 - Hypoxia inducible factor (HIF) transcription factors reside at the center of signaling pathways used by mammalian cells to sense and respond to low oxygen levels. While essential to maintain oxygen homeostasis, misregulation of HIF protein activity correlates with tumor development and metastasis. To provide artificial routes to target misregulated HIF activity, we identified small molecule antagonists of the HIF-2 transcription factor that bind an internal cavity within the C-terminal PAS domain of the HIF-2α subunit. Here we describe a new class of chiral small molecule ligands that provide the highest affinity binding, the most effective, isoform-selective inhibition of HIF-2 in cells, and trigger the largest protein conformation changes reported to date. The current results further illuminate the molecular mechanism of HIF-2 antagonism and suggest additional routes to develop higher affinity and potency HIF-2 antagonists.

AB - Hypoxia inducible factor (HIF) transcription factors reside at the center of signaling pathways used by mammalian cells to sense and respond to low oxygen levels. While essential to maintain oxygen homeostasis, misregulation of HIF protein activity correlates with tumor development and metastasis. To provide artificial routes to target misregulated HIF activity, we identified small molecule antagonists of the HIF-2 transcription factor that bind an internal cavity within the C-terminal PAS domain of the HIF-2α subunit. Here we describe a new class of chiral small molecule ligands that provide the highest affinity binding, the most effective, isoform-selective inhibition of HIF-2 in cells, and trigger the largest protein conformation changes reported to date. The current results further illuminate the molecular mechanism of HIF-2 antagonism and suggest additional routes to develop higher affinity and potency HIF-2 antagonists.

UR - http://www.scopus.com/inward/record.url?scp=84939192271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939192271&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.5b00529

DO - 10.1021/acs.jmedchem.5b00529

M3 - Article

C2 - 26226049

AN - SCOPUS:84939192271

VL - 58

SP - 5930

EP - 5941

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 15

ER -